Clinical Trials Browser

PIK3CA-Mutated Cancers × pembrolizumab × 30 days × Clear all

NCT06496568 2026-03-18

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

Phase 1 Recruiting

PIK3CA-Mutated Cancers